Helicid

Helicid is an intravenous formulation of the proton‑pump inhibitor omeprazole, supplied as a prescription‑only product in the European Union. The medication is presented in a sterile solution for injection, delivering the active ingredient directly into the bloodstream to achieve rapid suppression of gastric acid secretion. Helicid is classified as a gastro‑protective agent and is used under medical supervision for several acid‑related conditions in clinical practice.

Helicid is indicated for several gastrointestinal disorders where reduction of gastric acidity is required.

- Treatment of confirmed gastric and duodenal ulcers to promote healing and relieve pain. - Prevention and treatment of stress‑related mucosal damage in critically ill or hospitalized patients. - Management of gastro‑oesophageal reflux disease (GERD) symptoms, including heartburn and acid regurgitation. - Adjunct therapy in Helicobacter pylori eradication regimens to increase eradication rates. - Use in patients at risk of acid‑related complications after major surgery or intensive‑care procedures.

Like other proton‑pump inhibitors, Helicid may cause a range of adverse effects, most of which are mild and reversible. Most patients tolerate the medication well, but monitoring is advised for certain reactions.

Common: - Headache - Diarrhoea or loose stools - Nausea or mild abdominal discomfort - Flatulence or bloating - Dizziness - Injection site reactions such as erythema or pain

Serious: - Severe allergic reactions including anaphylaxis - Clostridioides difficile‑associated colitis - Persistent low magnesium levels (hypomagnesemia) with long‑term use - Acute interstitial nephritis - Liver enzyme elevations

Before initiating Helicid, clinicians should evaluate patient history and consider specific safety concerns to minimize risk.

- Assess for known hypersensitivity to omeprazole or other PPIs. - Use cautiously in patients with severe liver impairment; dose adjustment may be required. - Monitor magnesium levels during prolonged therapy, especially in the elderly. - Evaluate the need for long‑term use, as chronic suppression of acid may increase infection risk. - Consider alternative therapy in patients with a history of Clostridioides difficile infection. - Avoid concomitant use with drugs that require gastric acidity for absorption unless clinically justified. - Review renal function periodically if the patient has pre‑existing kidney disease.

Helicid can affect the pharmacokinetics of several medicines; awareness of potential interactions helps ensure safe co‑administration and appropriate monitoring. Clinicians should review patient medication lists before prescribing.

Avoid: - Antiretroviral agents such as atazanavir or nelfinavir. - Antifungal drugs that require acidic environment (ketoconazole, itraconazole). - Oral clopidogrel, which may have reduced activation.

Use with caution: - Warfarin, due to possible increase in INR; monitor coagulation. - Digoxin, as serum levels may rise. - Methotrexate, especially high‑dose, because renal clearance may be reduced.